- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- Bristol Myers Squibb faces revenue compression due to European exclusivity loss and US pricing limits after product required FDA approval.
The market responded negatively to management concerns regarding Bristol-Myers Squibb's business challenges.
1 report, 1 independent
Updated Aug 13
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The market responded negatively to management concerns regarding Bristol-Myers Squibb's business challenges.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Bristol-Myers Squibb
American pharmaceutical company
Related events
- Market competition observed in the large-cap healthcare sector involving Bristol-Myers Squibb and Orion OYJ.
- Manufacturers Life Insurance Company reduced its share position in Bristol-Myers Squibb.
- Cocrystal Pharma and Bristol-Myers Squibb are competing for investment as healthcare companies.
- MarketBeat reported consensus analyst targets and compared financial health for Bristol-Myers Squibb and Shionogi & Co., Ltd.
- Bristol-Myers Squibb and Johnson & Johnson are both companies that are currently targets of LB Pharmaceuticals.
Coverage
Newest first; wire copies grouped- StockStoryBMY Q2 Deep Dive: Pipeline Progress, Guidance Revision, and Strategic Partnerships Shape Outlook Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced better-than-expected revenue in Q2